CTLA4 and neoplasm: As tumor cells and infiltrating T cells face a nutrient-poor environment in vivo, this observation could be important for the use of metformin or 2DG as an adjuvant to anticancer therapies that do not directly target the PD-1/PD-L1 axis, such as, for example, immune-check point inhibitors targeting CTLA4.